Melanoma: all 3,073 studies

Page 6 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
• Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.RecruitingNCT02907827Not applicable
• Ontario-wide Cancer TArgeted Nucleic Acid EvaluationRecruitingNCT02906943
• Prospective Melanoma DatabaseRecruitingNCT02884362
• Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered LymphocytesRecruitingNCT02870244Phase 1
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable PrimaryRecruitingNCT02828202
• Duration of Anti-PD-1 Therapy in Metastatic MelanomaRecruitingNCT02821013Phase 3
• Molecular Analysis of Childhood and Adolescent Melanocytic LesionsRecruitingNCT02775643
• Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced MelanomaRecruitingNCT02673970
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2
• Cytokine-induced Killer Study for Patients With Stage II MelanomaNot yet recruitingNCT02498756Phase 2
• Project: Every Child for Younger Patients With CancerRecruitingNCT02402244
• Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With MelanomaRecruitingNCT01946373Phase 1
• Modified Vaccine for High Risk or Low Residual Melanoma PatientsRecruitingNCT01898039Phase 1/2
• In Vivo Real-time Detection of Circulating Melanoma CellsRecruitingNCT01776905
• Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruitingNCT01772771
• A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsRecruitingNCT01638676Phase 1/2
• Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal MelanomaRecruitingNCT01438658
• Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of TreatmentRecruitingNCT01205815
• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by invitationNCT00923026
• Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic TumorsRecruitingNCT00722228Phase 1/2
• Characterization of the Melanoma-Specific Immune ResponseRecruitingNCT00368615
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaRecruitingNCT00040352
• Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT00001823
• Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted
• Sun Protection and Tanning Awareness in Rural SchoolsCompletedNCT06694571Not applicableResults posted
• AI-based Medical Device Validation for Early Melanoma DetectionCompletedNCT06221397Results posted
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted
• A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial SettingsCompletedNCT05954546Results posted
• Bioequivalence Binimetinib 3 x 15 mg and 45 mg FormulationsCompletedNCT05810740Phase 1Results posted
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedNCT05764395Phase 2Results posted
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedNCT05714553Phase 1/2Results posted
• Enhancing Skin Cancer Early Detection and Treatment in Primary CareCompletedNCT05675709Not applicableResults posted
• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted
• A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingNCT05625399Phase 3Results posted
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).CompletedNCT05578872Phase 1/2Results posted
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 2Results posted
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedNCT05542342Phase 2Results posted
• A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During SurgeryTerminatedNCT05457842Phase 2Results posted
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminatedNCT05308901Phase 2Results posted
• A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedNCT05297565Phase 3Results posted
• Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the USCompletedNCT05260684Results posted
• Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)CompletedNCT05259696Phase 1/2Results posted
• Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
• Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous LesionsCompletedNCT05172232Results posted
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsTerminatedNCT05169437Phase 2Results posted
• GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2TerminatedNCT05130255Phase 1Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedNCT05116202Phase 1/2Results posted
• Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in MelanomaCompletedNCT05105100Results posted
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results posted
• A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingNCT05061134Phase 2Results posted
• Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)CompletedNCT05061017Phase 2Results posted
• Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following ResectionTerminatedNCT05060003Phase 2Results posted
• KZR-261 in Subjects With Advanced Solid MalignanciesTerminatedNCT05047536Phase 1Results posted
• Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsCompletedNCT05003622Phase 1Results posted
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedNCT05002569Phase 3Results posted
• A Study of SEA-CD40 Given With Other Drugs in CancersCompletedNCT04993677Phase 2Results posted
• Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedNCT04985604Phase 2Results posted
• Incidence of Melanoma and Non-melanoma Skin Cancer in People With VitiligoCompletedNCT04969419Results posted
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results posted
• A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)TerminatedNCT04913220Phase 1/2Results posted
• ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic MelanomaTerminatedNCT04904185Phase 1Results posted
• Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedNCT04899921Phase 2Results posted
• Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or HypnotherapyTerminatedNCT04899492Not applicableResults posted
• FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedNCT04894994Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results posted
• Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced MelanomaCompletedNCT04796194Phase 2Results posted
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedNCT04789668Phase 1/2Results posted
• Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaTerminatedNCT04768881Phase 2Results posted
• CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaTerminatedNCT04698187Phase 2Results posted
• CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaTerminatedNCT04695977Phase 2/3Results posted
• Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaTerminatedNCT04655157Phase 1/2Results posted
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
• Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal MelanomaTerminatedNCT04589832Phase 1/2Results posted
• Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryTerminatedNCT04588246Phase 3Results posted
• LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory MelanomaCompletedNCT04577807Phase 2Results posted
• BO-112 With Pembrolizumab in Unresectable Malignant MelanomaCompletedNCT04570332Phase 2Results posted
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminatedNCT04543188Phase 1Results posted
• A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentCompletedNCT04526899Phase 2Results posted
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedNCT04526730Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician AccessCompletedNCT04420273Not applicableResults posted
• Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceTerminatedNCT04410445Phase 3Results posted
• Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. NivolumabCompletedNCT04401995Phase 2Results posted
• UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaCompletedNCT04382664Phase 2Results posted
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesCompletedNCT04370704Phase 1/2Results posted
• A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT04337931Phase 2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedNCT04305041Phase 1/2Results posted
• Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedNCT04303169Phase 1/2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedNCT04221438Phase 2Results posted

← Melanoma overview